Um medicamento usado para o alcoolismo pode tratar o câncer ao atingir macrófagos
Um grupo de pesquisa liderado por Yuya Terashima, da Universidade de Tóquio, descobriu que uma droga usada para o alcoolismo pode tratar Câncer visando macrófagos.
De acordo com dados da OMS e da Agência Internacional de Pesquisa sobre o Câncer (IARC), houve 18.1 milhões de novos casos e 9.6 milhões de mortes em 2018. Um em cada 5 homens e uma em cada 6 mulheres em todo o mundo desenvolvem câncer durante a vida, e um em cada 8 homens e uma em cada 11 mulheres morre da doença. Em todo o mundo, o número total de pessoas vivas nos 5 anos seguintes ao diagnóstico de cancro, denominado prevalência de 5 anos, é estimado em 43.8 milhões.
Câncer de pulmão é o tipo de câncer mais comum em homens (14.5%) e a principal causa de morte em homens (22%). Isto é seguido por câncer de próstata (13.5%), câncer colorretal (10.9%), & câncer de fígado (9.5%). Entre as mulheres, câncer de mama é de aproximadamente 25%, seguido pelo câncer de pulmão (13.8%), câncer colorretal (9.5%) e câncer cervical (6.6%).
Construindo um treatment to battle malignant growth remains one of the most troublesome difficulties in medicinal research. Malignant growth owes its infamous personality to the way that the disease cells utilize the host’s own resistant framework to develop and spread, finally getting savage. Invulnerable cells like macrophages, which usually battle to ensure ordinary cells, are commandeered by dangerous disease cells, and populate the earth around the tumors, turning out to be tumor-related macrophages (TAMs).
Actually, it was discovered that the malignant tissue of patients for whom Imunoterapia was not fruitful was in fact rich in macrophages, affirming the connection between the disease and the TAMs. It is these TAMs that produce flagging proteins like chemokines and trigger the inhibitory resistant checkpoint discharges that make an immunosuppressive tumor condition, which ensures the malignant growth cells and permits their quickened development. Since the TAMs encourage the spreading of malignant células de crescimento, managing them as a remedial methodology for battling disease has picked up consideration as of late.
A research team from the Tokyo University of Science, under the direction of Yuya Terashima saw this as an opportunity to look into the field of developing new anti-malignant growth drugs. Their original work in Nature Immunology 2005 revealed the disclosure of another objective protein called FROUNT, which is connected to the guidelines and development of the TAMs. In this way, FROUNT was directly linked to TAM rules because it increased “chemokine signaling,” a type of cell communication that is necessary for TAM gathering and movement.
At that point, so as to diminish any symptoms, the group additionally built up an autonomous technique for restricting the impact of FROUNT on chemokine motion by repressing the connection between the two. The group screened 131,200 mixes and focused on disulfiram, a medication used to treat liquor abuse, and referred to for its potential as an enemy of malignant growth tranquilizer. This medication was found to legitimately tie to the FROUNT site, making FROUNT inaccessible for collaboration with the parts of chemokine flagging.
Considering the outcomes, Terashima clarifies, “When tried on mice, disulfiram repressed the development of macrophages and stifled the development of malignant growth cells. Thus, our findings reveal a new way to treat cancer that can stop the growth of cancer cells that are hard for immune systems to detect when used together with disulfiram.
Hopefully, we will get to see new therapies in the treatment of cancer.
